Vendor Intelligence Report: BeiBangAn
Published 12 Nov 2026. 33-page investigative report on who is behind BeiBangAn: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
BeiBangAn is a peptide-by-peptide decision, not a blanket buy/avoid call. Across 74 Finnrick lab tests, the overall record is 53 pass / 20 fail, a 72% pass rate. GHK-Cu is best-rated but thinly sampled; retatrutide and tirzepatide carry the deeper usable GLP-1 signal; BPC-157 is materially weaker. Ratings can contract under stricter purity/fill scoring, so current-lot checking still matters.
BBA now has a real public COA surface, but it does not solve traceability. The Test Reports page moved from empty to populated with Janoshik links; the reviewed July 2026 certificates show client/manufacturer BBA while leaving Batch as ‘Unknown.’ They evidence submitted-sample testing, not that a shipped vial maps to the tested lot.
The business layer is thinner than the catalogue. Public sources reviewed did not verify a BeiBangAn legal entity, natural-person owner, named quality lead, or batch-release decision-maker; that is a research limitation, not proof of absent competence. The site’s “25+ years”/“2001” language sits beside a 2026 web footprint, privacy-shielded domain records, and an empty Terms page.
The clearest non-lab risk is channel authentication. Multiple Telegram invites, a lapsed brand-matching domain, lookalike complaints, and search-poisoning pages make genuine BBA harder to verify. Network artifacts connect the build/catalogue orbit to LNpeptide and Andy Peps Studio without proving common ownership.
Inside the full report:
- Per-product pass/fail record and methodology-divergence charts for all 7 products
- Janoshik certificate review, including July 2026 Batch ‘Unknown’ findings
- RDAP and certificate-transparency analysis for current and lapsed BBA domains
- Hostinger staging clone, WordPress media, LNpeptide, and Andy Peps Studio artifacts
- Forum and Telegram copycat timeline across GLP-1 Forum, MESO-Rx, Looksmax, TikTok
- BBA empty-terms review versus LNpeptide purity/fill/reship terms
Risk assessment
- Batch-to-vial traceability risk — high: BBA’s July 2026 Janoshik certificates #202682–#202691 list Batch ‘Unknown’ and no public lot-to-vial mapping, so a buyer cannot link a shipped vial to a report.
- Product-specific quality risk — BPC-157, PT-141, tesamorelin — high: Finnrick rates BPC-157 54.07% over 4 tests, PT-141 59.66% over 3 tests, and tesamorelin 46.51% on 1 test, materially weaker than BBA’s retatrutide/tirzepatide/GHK-Cu record.
- Product-specific quality caution — semaglutide — medium: Semaglutide sits at 68.82% across 4 Finnrick tests, below BBA’s better-tested GLP-1 products and too thin to treat as a strong choice.
- Copycat / brand-confusion risk — high: Multiple BBA Telegram invite links, a lapsed beibangan.com, fake-group complaints in 2026, and no authoritative channel/authorized-reseller list make impersonation a material purchase risk.
- Identity and ownership opacity — medium: No BeiBangAn legal entity or natural-person controller was verified; the domain is privacy-registered and public ‘25+ years’ / ‘2001’ claims conflict with the 2026 web footprint.
- After-sales recourse risk — medium: BBA’s Terms and Conditions page contains no terms text; no refund, purity/fill, reship, dispute, or governing-law policy was found.
- Supplier-network continuity risk — medium: BBA shares build/catalogue artifacts with LNpeptide, whose FAQ says operations were previously ‘under investigation’ and resumed; BBA’s dependency on that network is unresolved.